27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
MDT-OS and ORR-LDR were weakly-to-moderately correlated with the Preclinical Alzheimer's Cognitive Composite (PACC5) (r = 0.3-0.44, p < .001) and with several other measures of episodic memory, processing speed, and executive function. 5 key findings →
Participants: 172 Evidence: low
Full summary, score breakdown and related studies → Original source
We received completed questionnaires from physicians for 45 patients. 5 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
Despite the demonstrated benefits of computerized cognitive training for older adults, little is known about the determinants of training behavior. 3 key findings →
Participants: 219 Evidence: low
Full summary, score breakdown and related studies → Original source
Mild cognitive impairment (MCI) is a prodromal stage of dementia, and its early detection is critical for improving clinical outcomes. 5 key findings →
Participants: 80 Evidence: low
Full summary, score breakdown and related studies → Original source
ANOVA and Bayesian t-test found no significant differences between the task when it was remotely self-administered by participants at home compared to when it was taken under controlled lab conditions. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
This is the first study to investigate the effect of MAKSCog, an individualised CCT, specifically developed for people with different subtypes of MCI. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
A total of 103 participants completed all investigations and were included in the analysis. 5 key findings →
Participants: 103 Evidence: low
Full summary, score breakdown and related studies → Original source
Average performance on the episodic memory (Prices) smartphone task showed the highest accuracy (AUC = 0.77) to distinguish Aβ status. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Augmenting traditional genome-wide association studies (GWAS) with advanced machine learning algorithms can allow the detection of novel signals in available cohorts. 3 key findings →
Participants: 42 Evidence: low
Full summary, score breakdown and related studies → Original source
This approach offers a sensitive method for identifying individuals at high risk for AD-related cognitive decline. 1 key finding →
Participants: 954 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) may cause damage to the memory cells permanently, which results in the form of dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Due to the COVID-19 pandemic, most memory clinics have had to suspend their activities. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The increasing ageing global population is causing an upsurge in ailments related to old age, primarily dementia and Alzheimer's disease, frailty, Parkinson's, and cardiovascular disease, but also a general need for general eldercare as well as active and healthy ageing. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
On clinical data, this innovative approach for early diagnosis might provide more insight into pathophysiological processes underlying degenerative changes, as well as toward a personalized risk evaluation for pharmacological, nonpharmacological, and rehabilitation treatments. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study of Alzheimer's disease (AD), the most common cause of dementia, faces challenges in terms of understanding the cause, monitoring the pathogenesis, and developing early diagnoses and effective treatments. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Higher-order factors (e.g., emotional distress, subjective health), which reflect complex interactions between various aspects of an individual, were more important than narrowly defined factors (e.g., clinical and behavioral indicators) when evaluated concurrently to predict cognitive impairment and dementia. 2 key findings →
Design: post-hoc analysis Participants: 9,979 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our results demonstrate that the repeatability of speech features extracted using open-source tool kits is low. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
By 2040 more people in Scotland are projected to die with palliative care needs, and the complexity of need will increase markedly. 3 key findings →
Participants: 34 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dual-task gait and other detailed gait metrics provide value for identifying CF above gait speed alone. 1 key finding →
Participants: 41 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Easily accessible biomarkers for Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD), and related neurodegenerative disorders are urgently needed in an aging society to assist early-stage diagnoses. 4 key findings →
Participants: 377 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The deficits characteristic of Alzheimer's disease (AD) are believed to result, at least in part, from the neurotoxic effects of beta-amyloid peptides, a set of 39-43 amino acid fragments derived proteolytically from beta-amyloid precursor protein (APP). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Amyloid precursor protein (APP), ADAM 10, and beta-site-APP cleaving enzyme (BACE) alterations were evaluated in platelets of 31 patients with Alzheimer disease (AD) and 15 age-matched controls. 2 key findings →
Participants: 31 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There were observable geographic variations in education (range 13.4-16.2 years, Figure 1), age (range 66.7-72.4 years) and severable modifiable risk factors for dementia across Tasmania, Australia. 5 key findings →
Design: longitudinal study Participants: 8,891 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This comprehensive review examines the integration of Quantitative Electroencephalography (qEEG) and Artificial Intelligence (AI) in the detection and diagnosis of Alzheimer's Disease (AD). 5 key findings →
Participants: 890 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We observed that existing AI-assisted dietary assessment tools are integrated with mobile/web-based applications to provide a user-friendly interface. 5 key findings →
Participants: 17,613 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
10 of the 1,102 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →